Manuel Fernandez
General Practice · Miami, FLNPI 1265402051
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Lilly USA, LLC at 25.6% of the total. Reporting peaked in 2021 at $418 and has fallen 95.0% since, to $21 in 2025.
Across 48 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$271
- AbbVie$166
- Johnson & Johnson$164
- AstraZeneca$158
- GSK$95
- Sanofi-aventis U.S. LLC$67
- plus $135 from 3 others
Across 188 payments — averaging $17,479 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amneal Pharmaceuticals LLC$990K
- Eli Lilly$760K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$674K
- E.r. Squibb & Sons, L.L.C.$331K
- Avanir Pharmaceuticals, Inc.$275K
- Sage Therapeutics, LLC$250K
- plus $6K from 1 others
What the payments were for
- Food & beverage$1,057100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 16 | $271 |
| AbbVie(2 entities) | 3 | $166 |
| Johnson & Johnson | 9 | $164 |
| AstraZeneca | 3 | $158 |
| GSK | 5 | $95 |
| Sanofi-aventis U.S. LLC | 4 | $67 |
| Novo Nordisk | 4 | $63 |
| Boehringer Ingelheim | 3 | $57 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,057 in reported general payments places this provider in the 80th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $128,689 |
| EliquisApixaban | 69 | $52,548 |
| VascepaIcosapent Ethyl | 84 | $32,601 |
| XareltoRivaroxaban | 22 | $24,093 |
| JardianceEmpagliflozin | 22 | $20,456 |
| FarxigaDapagliflozin Propanediol | 26 | $16,994 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 27 | $16,160 |
| Xigduo XrDapaglifloz Propaned/Metformin | 25 | $14,126 |
| TrulicityDulaglutide | 14 | $13,233 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $12,042 |
| RestasisCyclosporine | 19 | $12,026 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $10,666 |
| LinzessLinaclotide | 13 | $7,907 |
| Tadalafil | 39 | $7,866 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $7,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $63 | $128,689132 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $57 | $36,61649 claims |
| AbbVieRestasis, Linzess, Lumigan, Alphagan P, Synthroid | $166 | $28,56580 claims |
| Johnson & JohnsonXarelto | $164 | $24,09322 claims |
| AstraZenecaFarxiga, Brilinta | $158 | $23,79241 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $95 | $16,12139 claims |
| Lilly USA, LLCTrulicity | $271 | $13,23314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,901 general practice providers in Florida.
Other general practice in Miami
- Idalia AcostaMiami$99K
- Eddie GomezMiami$59K
- Aladino ValienteMiami$24K
- Viviana WaichMiami$20K
- Libia RiosMiami$15K
- Jose CardonaMiami$15K
- Rosa HuguetMiami$15K
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.